Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Pembrolizumab & Gastroesophageal junction adenocarcinoma (GEJ) (MMR-d/MSI-H), FDA granted a tissue‑agnostic approval (May 23, 2017) for pembrolizumab in adult and pediatric patients with unresectable or metastatic MSI‑H/dMMR solid tumors that have progressed following prior treatment and have no satisfactory alternative options. This indication is explicitly site‑agnostic and applies irrespective of primary tumor origin, so Gastroesophageal junction adenocarcinoma (GEJ) (MMR-d/MSI-H) falls within the labeled population if unresectable/metastatic and previously treated (1, 2, 3).
[…